reports
Assured Guaranty Ltd: 1 director
A director at Assured Guaranty Ltd sold 40,000 shares at 81.510USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Reed’s Reports Second Quarter 2025 Results
Reed’s Reports Second Quarter 2025 Results Management to Host Conference Call Tomorrow at 8:30 a.m. ET NORWALK, Conn., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, is reporting financial results for the three and six months ended June 30, 2025. Q2 2025 Financial Highlights (vs. Q2 2024): Net sales were $9.5 million compared to $11.9 million.Gross profit was $0.8 million compared to $3.8 million, with gross margin of 8% compared to 32%. Excluding inventory writ...
Dorchester Minerals, L.P. Announces Second Quarter Results
Dorchester Minerals, L.P. Announces Second Quarter Results DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today the Partnership’s net income for the quarter ended June 30, 2025 of $12,347,000, or $0.25 per common unit. A comparison of the Partnership’s consolidated results for the quarters ended June 30, 2025 and 2024 are set forth below: Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024Operating Revenues$32,395,000 $37,360,000 $75,559,000 $68,339,000Net Income$12,347,000 $23,628,000 $29,989,00...
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and...
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 and Recent Corporate Highlights Announced launch of VYKAT XR and commencement of patient treatments on April 14, 2...
Reed’s Schedules Second Quarter 2025 Conference Call for August 13 at ...
Reed’s Schedules Second Quarter 2025 Conference Call for August 13 at 8:30 a.m. ET NORWALK, Conn., July 30, 2025 (GLOBE NEWSWIRE) -- Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, will host a conference call on Wednesday, August 13, 2025, at 8:30 a.m. Eastern time to discuss its financial results for the three months ended June 30, 2025. The Company’s results will be reported in a press release prior to the call. Reed’s management will host the conference call, followed by a question-and-answer per...
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on...
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET REDWOOD CITY, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its second quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, August 6, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results an...
Dorchester Minerals, L.P. Announces Its Second Quarter Distribution
Dorchester Minerals, L.P. Announces Its Second Quarter Distribution DALLAS, July 24, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (NASDAQ:DMLP) announced today the Partnership’s second quarter 2025 cash distribution. The distribution of $0.620216 per common unit represents activity for the three-month period ended June 30, 2025 and is payable on August 14, 2025 to common unitholders of record as of August 4, 2025. Cash receipts attributable to the Partnership’s Royalty Properties during the second quarter totaled approximately $26.6 million. Approximately 73% of these receipts ref...
Soleno Therapeutics Announces Pricing of $200 Million Public Offering ...
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. All of the shares are being sold by Soleno. In addition, Soleno has granted the underwriters a 30-day option to purchase up to an ad...
Soleno Therapeutics Announces Proposed $200 Million Public Offering of...
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell $200 million of shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of common stock. The proposed public offering is subject ...
Soleno Therapeutics Announces Preliminary Financial and Operational Re...
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary unaudited financial and operational results for the three months ended June 30, 2025: Soleno expects its net revenue from the sales of VYKATTM XR, for the three months ended June 30, 2025 to be between $31.0 million and $33.0 million....
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
HPP HUDSON PACIFIC PROPERTIES INC.
PSEC PROSPECT CAPITAL CORPORATION
NG. NOVAGOLD RESOURCES INC.
WELL WELLTOWER INC.
CDXS CODEXIS
CDTX CIDARA THERAPEUTICS
AMPH AMPHASTAR PHARMACEUTICALS INC
PZG PARAMOUNT GOLD NEVADA CORP.
NXRT NEXPOINT RESIDENTIAL TRUST INC.
GIII G-III APPAREL GROUP LTD.
OXM OXFORD INDUSTRIES INC.
THO THOR INDUSTRIES INC.
GRF EAGLE CAPITAL GROWTH FUND INC
MLP MAUI LAND & PINEAPPLE CO. INC.
SVRA SAVARA
CLRB CELLECTAR BIOSCIENCES
STKL SUNOPTA
RSSS INC.
BWB RESEARCH SOLUTIONS
DOMO BRIDGEWATER BANCSHARES
SONO DOMO INCORPORATED
A2JHXF SONOS
FGBI CEVA LOGISTICS AG
PVH FIRST GUARANTY BANCSHARES
AMPY PHILLIPS-VAN HEUSEN CORPORATION
INLX AMPLIFY ENERGY
FRHC INTELLINETICS
RZLT INC.
KYMR FREEDOM HOLDING CORP
WSC REZOLUTE
BTBT INC.
TERN KYMERA THERAPEUTICS
NUVB WILLSCOT MOBILE MINI HOLDINGS CORP
CTO BIT DIGITAL (N SHARES)
VERA TERNS PHARMACEUTICALS
IMRX NUVATION BIO INC (A)
XLO CONSOLIDATED-TOMOKA LAND CO
SSBK VERA THERAPEUTICS INC
NCDL IMMUNEERING CORP
PMNT XILIO THERAPEUTICS INC
NYC SOUTHERN STATES BANCSHARES INC
ACTU NUVEEN CHURCHILL DIRECT LENDING CORP
SUNS PERFECT MOMENT LTD.
MBRX NEW YORK CITY REIT
HYMC INC.
THAR ACTUATE THERAPEUTICS INC.
FGEN SUNRISE REALTY TRUST
CCIF MOLECULIN BIOTECH INC.
HYCROFT MINING HOLDING CORPORATION
THARIMMUNE INC.
FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
Soleno Therapeutics Inc: 1 director
A director at Soleno Therapeutics Inc sold 3,830 shares at 82.760USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR...
Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025 REDWOOD CITY, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that two abstracts featuring data on VYKAT™ XR (diazoxide choline) extended-release tablets, previously known as DCCR, have been selected for presentation at the Annual Meeting of the Endocrine Society (ENDO 2025), which is being held July 12-15, 2025, in San Francisco...
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
HPP HUDSON PACIFIC PROPERTIES INC.
PSEC PROSPECT CAPITAL CORPORATION
MTH MERITAGE HOMES CORPORATION
FFIN FIRST FINANCIAL BANKSHARES INC
CDXS CODEXIS
CABO CABLE ONE INC.
AMPH AMPHASTAR PHARMACEUTICALS INC
PZG PARAMOUNT GOLD NEVADA CORP.
ADC AGREE REALTY CORPORATION
GIII G-III APPAREL GROUP LTD.
OXM OXFORD INDUSTRIES INC.
THO THOR INDUSTRIES INC.
TTI TETRA TECHNOLOGIES INC.
VRA VERA BRADLEY INC.
MLP MAUI LAND & PINEAPPLE CO. INC.
SVRA SAVARA
STKL SUNOPTA
RSSS INC.
BWB RESEARCH SOLUTIONS
BHC BRIDGEWATER BANCSHARES
DOMO BAUSCH HEALTH COMPANIES INC.
SONO DOMO INCORPORATED
BLDR SONOS
AMPY BUILDERS FIRSTSOURCE
INLX INC.
DCTH AMPLIFY ENERGY
RZLT INTELLINETICS
WSC INC.
GRNT DELCATH SYSTEMS
TERN REZOLUTE
NUVB INC.
CTO WILLSCOT MOBILE MINI HOLDINGS CORP
VERA GRANIT SKOPKE
IMRX TERNS PHARMACEUTICALS
XLO NUVATION BIO INC (A)
SSBK CONSOLIDATED-TOMOKA LAND CO
GECC VERA THERAPEUTICS INC
BARK IMMUNEERING CORP
MNR XILIO THERAPEUTICS INC
NCDL SOUTHERN STATES BANCSHARES INC
SUNS GREAT ELM CAPITAL CORP
MBRX ORIGINAL BARK CO
WHLR MACH NATURAL RESOURCES LP
HYMC NUVEEN CHURCHILL DIRECT LENDING CORP
THAR SUNRISE REALTY TRUST
RVYL MOLECULIN BIOTECH INC.
INUV WHEELER REAL ESTATE INVESTMENT TRUST INC.
HYCROFT MINING HOLDING CORPORATION
THARIMMUNE INC.
RYVYL INC.
INUVO INC.
Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 Un...
Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference REDWOOD CITY, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today highlighted new data on VYKATTM XR (diazoxide choline) extended-release tablets, previously known as DCCR, at the 2025 United in Hope: International Prader-Willi Syndrome Conference. “We believe that these data reveal critical insights on the potential...
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
HPP HUDSON PACIFIC PROPERTIES INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MOD MODINE MANUFACTURING COMPANY
GLP GLOBAL PARTNERS LP
CDXS CODEXIS
BUSE FIRST BUSEY CORPORATION
AMPH AMPHASTAR PHARMACEUTICALS INC
PZG PARAMOUNT GOLD NEVADA CORP.
GIII G-III APPAREL GROUP LTD.
OXM OXFORD INDUSTRIES INC.
CIA CITIZENS INC. CL A
FLL FULL HOUSE RESORTS INC.
ALOT
MLP ASTRONOVA INC.
BCBP MAUI LAND & PINEAPPLE CO. INC.
BRT BCB BANCORP INC.
STKL BRT APARTMENTS
RSSS SUNOPTA
BWB INC.
BHC RESEARCH SOLUTIONS
SONO BRIDGEWATER BANCSHARES
AMPY BAUSCH HEALTH COMPANIES INC.
ENX SONOS
WSC AMPLIFY ENERGY
DLHC EATON VANCE NEW YORK MUNICIPAL BOND FUND
GRNT WILLSCOT MOBILE MINI HOLDINGS CORP
NUVB DALEIGH HOLDINGS CORP
XLO GRANIT SKOPKE
NVCT NUVATION BIO INC (A)
TCBX XILIO THERAPEUTICS INC
BARK NUVECTIS PHARMA INC
OPAL THIRD COAST BANCSHARES INC
GTE ORIGINAL BARK CO
SRM OPAL FUELS INC
MNR GRAN TIERRA ENERGY INC.
SDHC SRM ENTERTAINMENT INC
NCDL MACH NATURAL RESOURCES LP
SUNS SMITH DOUGLAS HOMES CORP
EVM NUVEEN CHURCHILL DIRECT LENDING CORP
LION SUNRISE REALTY TRUST
HYMC EATON VANCE INSD CALIF MUN BD FD
LIONSGATE STUDIOS CORP
HYCROFT MINING HOLDING CORPORATION
Soleno Therapeutics Announces Multiple Presentations at the 2025 Unite...
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research, and the International Prader-Willi Syndrome Organisation REDWOOD CITY, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced one oral and six poster presentatio...
Reed’s to Participate in OTC Markets Virtual Investor Conference on Ju...
Reed’s to Participate in OTC Markets Virtual Investor Conference on June 26 NORWALK, Conn., June 18, 2025 (GLOBE NEWSWIRE) -- Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced its participation in the upcoming OTC Markets Virtual Investor Conference on Thursday, June 26, 2025. Reed’s management team will hold virtual 1x1 meetings throughout the day and host a presentation at 2:00pm ET. This will be a live, interactive event where investors are invited to ask the Company questions in re...
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
GLP GLOBAL PARTNERS LP
CDXS CODEXIS
BUSE FIRST BUSEY CORPORATION
AMPH AMPHASTAR PHARMACEUTICALS INC
OXM OXFORD INDUSTRIES INC.
PLYA PLAYA HOTELS & RESORTS
BCBP BCB BANCORP INC.
BRT BRT APARTMENTS
STKL SUNOPTA
SONO INC.
ENX SONOS
GRNT EATON VANCE NEW YORK MUNICIPAL BOND FUND
TCBX GRANIT SKOPKE
TYRA THIRD COAST BANCSHARES INC
BARK TYRA BIOSCIENCES INC
OPAL ORIGINAL BARK CO
PRME OPAL FUELS INC
GTE PRIME MEDICINE INC
SDHC GRAN TIERRA ENERGY INC.
NCDL SMITH DOUGLAS HOMES CORP
EVM NUVEEN CHURCHILL DIRECT LENDING CORP
EATON VANCE INSD CALIF MUN BD FD
Soleno Therapeutics Announces Submission and EMA Validation of Marketi...
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno’s Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DC...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.